The prognosis of non-small cell lung cancer varies depending on the specific subtype and the stage of cancer at diagnosis.

Younger patients with lung cancer are more likely to have mutations that allow for targeted therapies, which can lead to more ...

ZL-1310 earns fast track designation in extensive-stage small cell lung cancer after early trial data showed tumor shrinkage ...

A study of human tumor cells implanted in mice from the MacPherson Lab at Fred Hutch describes a new way to screen for the ...

An investigational viral immunotherapy extended survival compared with standard care for patients with advanced non-small cell lung cancer who had inadequate response to immune checkpoint ...

"Optune Lua is an innovative and urgently needed new approach for treating metastatic non-small cell lung cancer," said Joachim ... extension in overall survival. These results and the lack ...

“These outcomes suggest that patients can experience prolonged disease control and survival after stopping ... patients with advanced non-small cell lung cancer who were prescribed immune ...

The HER2-targeted therapy zongertinib demonstrated clinical benefits for previously treated patients with advanced HER2-mutant non-small cell lung cancer ... free survival (PFS) of 12.4 ...